お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
980002

ピラジナミドの市場規模:患者タイプ、流通チャネル、地域 - シェア、見通し、および機会分析(2020年~2027年)

Pyrazinamide Market, by Patient Type, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

出版日: | 発行: Coherent Market Insights | ページ情報: 英文 149 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=107.06円
ピラジナミドの市場規模:患者タイプ、流通チャネル、地域 - シェア、見通し、および機会分析(2020年~2027年)
出版日: 2020年12月22日
発行: Coherent Market Insights
ページ情報: 英文 149 Pages
納期: 2-3営業日
  • 全表示
  • 概要
  • 目次
概要

世界のピラジナミド市場の成長を促進する要因には、世界における結核による負担増加が挙げられます。米国疾病予防管理センターによると、2017年には世界において1,000万人が結核を患い、130万人の結核関連の死者が出ています。

さらに、2018年に発表されたWHOのデータによると、結核による支出は、治療と予防に92億米ドル、追加の経済的費用と生産性の損失に120億米ドルとなり、毎年210億米ドルを超えています。このことから、結核の治療へのヘルスケア費の増加は、同市場の成長を促進すると予想されています。

当レポートは、世界のピラジナミド市場について調査しており、市場機会や動向、成長および抑制要因、患者タイプ・流通チャネル・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

目次

第1章 調査目的・前提条件

第2章 市場概要

  • レポートの概要
    • 市場の定義と範囲
  • エグゼクティブサマリー
    • 患者タイプ別
    • 流通チャネル別
    • 地域別
  • Coherent Opportunity Map (COM)

第3章 市場力学、規制、および動向分析

  • 市場力学
    • 成長要因
    • 抑制要因
    • 市場機会
  • 市場動向
  • 主な発展
  • 影響分析
  • 合併と買収
  • 新製品の発売
  • 技術の概要
  • PEST分析

第4章 Covid-19パンデミックの影響

  • COVID19影響分析
  • 新しい開発

第5章 市場分析:患者タイプ別(2016-2027)

  • イントロダクション
  • 大人
  • 小児

第6章 市場分析:流通チャネル別(2016-2027)

  • イントロダクション
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第7章 市場分析:地域別(2016-2027)

  • イントロダクション
  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • 中東
  • アフリカ

第8章 競合情勢

  • 企業プロファイル
    • Pure Chemistry Scientific
    • LGM Pharma
    • City Chemical
    • TCI
    • HBCChem
    • Alfa Chemistry
    • Toronto Research Chemicals
    • Acros Organics
    • AlliChem
    • Waterstone Technology

第9章 セクション

目次

Title:
Pyrazinamide Market, by Patient Type (Adult and Pediatric), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027.

Pyrazinamide (PZA) is a medication used to treat tuberculosis. Moreover, for active tuberculosis, it is often used with rifampicin, isoniazid, and either streptomycin or ethambutol. It is not generally recommended for the treatment of latent tuberculosis. Pyrazinamide kills non-replicating persister cells that other medication of TB fail to kill, and for which it became important drug for inclusion in any drug combinations for treating drug susceptible and drug-resistant TB such as MDR-TB. It acts variably compared to other antibiotics by inhibiting energy production, trans-translation, and co-enzyme A required for persister survival. The increasing mutation in drug targeted gene is marking bacterial strain more resistant to PZA drug. The recently panD mutations gene was found along with pncA or rpsA mutations gene in bacterial resistant strains.

Market Dynamics

The high burden of TB is expected to drive growth of the market. For instance, according to the WHO, in 2017, 87% of new TB cases occurred in 30 high TB burden countries. The eight countries out of 30 include India, China, Indonesia, the Philippines, Pakistan, Nigeria, Bangladesh, and South Africa, which accounted for two thirds of the new TB cases.

The increasing global burden of TB is expected to drive the pyrazinamide market growth. For instance, according to the Centre for Disease Control and Prevention, in 2017, 10.0 million people around the world suffered from TB, and there were 1.3 million TB-related deaths worldwide.

Moreover, according to the WHO data published in 2018, TB costs the world over US$ 21 billion each year, including US$ 9.2 billion for treatment and prevention, and US$ 12 billion in additional economic costs and lost productivity. Thus, increasing healthcare spending on treatment of TB is expected to drive growth of the market.

Moreover, according to the WHO, treatment for multi-drug resistant TB (MDR-TB) takes 20-26 months, and average cost of treatment in the U.S. is around US$ 294,000.

Moreover, increasing investments in R&D activities for development of novel therapies for treatment of TB is expected to restrain growth of the pyrazinamide drugs market. For instance, according to the Tuberculosis Research Funding Trends 2005-2017 reports, global investment in TB research was valued at US$ 772 Million in 2017, with an increase of 6% (or US$ 46 million), compared to US$ 726 million in 2016.

Key features of the study:

  • This report provides in-depth analysis of the global pyrazinamide market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period: 2020-2027, considering 2019 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players.
  • It profiles key players in the global pyrazinamide market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include Pure Chemistry Scientific, LGM Pharma, TCI, HBCChem, Alfa Chemistry, Toronto Research Chemicals, Acros Organics, AlliChem, Waterstone Technology, City Chemical, EDQM, J & K SCIENTIFIC, Meryer (Shanghai) Chemical Technology, Energy Chemical, and Beijing Ouhe Technology.
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global pyrazinamide market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers of Infertility drugs and devices, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

  • Global Pyrazinamide Market, By Patient Type:
    • Adult
    • Pediatric
  • Global Pyrazinamide Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Pyrazinamide Market, By Region:
    • North America
      • By Country:
    • U.S.
    • Canada
      • By Patient Type:
    • Adult
    • Pediatric
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Europe
      • By Country:
    • U.K.
    • Germany
    • Italy
    • Spain
    • France
    • Russia
    • Rest of Europe
      • By Patient Type:
    • Adult
    • Pediatric
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Asia Pacific
      • By Country:
    • Australia
    • India
    • China
    • Japan
    • ASEAN
    • South Korea
    • Rest of Asia Pacific
      • By Patient Type:
    • Adult
    • Pediatric
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Latin America
      • By Country:
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
      • By Patient Type:
    • Adult
    • Pediatric
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Middle East
      • By Country:
    • GCC
    • Israel
    • Rest of Middle East
      • By Patient Type:
    • Adult
    • Pediatric
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Africa
      • By Country/Region:
    • South Africa
    • Central Africa
    • North Africa
      • By Patient Type:
    • Adult
    • Pediatric
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Company Profiles
      • Pure Chemistry Scientific*
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
      • LGM Pharma
      • City Chemical
      • TCI
      • HBCChem
      • Alfa Chemistry
      • Toronto Research Chemicals
      • Acros Organics
      • AlliChem
      • Waterstone Technology

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Patient Type
    • Market Snapshot, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Market Trends
  • Key Developments
  • Impact Analysis
  • Mergers & Acquisitions
  • New Product Launch
  • Technology Overview
  • PEST Analysis

4. Global Pyrazinamide Market - Impact of Coronavirus (Covid-19) Pandemic

  • COVID 19 Impact Analysis
  • New Developments

5. Global Pyrazinamide Market, By Patient Type, 2016 - 2027, (US$ million)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Adult
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Pediatric
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)

6. Global Pyrazinamide Market, By Distribution Channel, 2016 - 2027, (US$ million)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)

7. Global Pyrazinamide Market, By Region, 2016- 2027, (US$ Million)

  • Introduction
    • Market Share Analysis, By Patient Type, 2020 and 2027 (%)
    • Market Share Analysis, By Distribution Channel, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, By Region, 2017 - 2027
    • Regional Trends
  • North America
    • Market Share Analysis, By Patient Type, 2020 and 2027 (%)
    • Market Share Analysis, By Distribution Channel, 2020 and 2027 (%)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • U.S.
    • Canada
  • Europe
    • Market Share Analysis, By Patient Type, 2020 and 2027 (%)
    • Market Share Analysis, By Distribution Channel, 2020 and 2027 (%)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Share Analysis, By Patient Type, 2020 and 2027 (%)
    • Market Share Analysis, By Distribution Channel, 2020 and 2027 (%)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Market Share Analysis, By Patient Type, 2020 and 2027 (%)
    • Market Share Analysis, By Distribution Channel, 2020 and 2027 (%)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Middle East
    • Market Share Analysis, By Patient Type, 2020 and 2027 (%)
    • Market Share Analysis, By Distribution Channel, 2020 and 2027 (%)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • Market Share Analysis, By Patient Type, 2020 and 2027 (%)
    • Market Share Analysis, By Distribution Channel, 2020 and 2027 (%)
    • Market Size and Forecast, By Country/Region, 2016 - 2027, (US$ Million)
    • North Africa
    • Central Africa
    • South Africa

8. Competitive Landscape

  • Company Profiles
    • Pure Chemistry Scientific
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • LGM Pharma
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • City Chemical
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • TCI
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • HBCChem
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Alfa Chemistry
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Toronto Research Chemicals
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Acros Organics
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • AlliChem
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Waterstone Technology
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies

9. Section

  • References
  • Research Methodology
  • About Us and Sales Contact
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.